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Many industrialized countries have implemented routine immunization policies for older adults, but sim-
ilar strategies have not been widely implemented in low- and middle-income countries (LMICs). In March
2017, the World Health Organization (WHO) convened a meeting to identify policies and activities to pro-
mote access to vaccination of older adults, specifically in LMICs. Participants included academic and
industry researchers, funders, civil society organizations, implementers of global health interventions,
and stakeholders from developing countries with adult immunization needs. These experts reviewed vac-
cine performance in older adults, the anticipated impact of adult vaccination programs, and the chal-
lenges and opportunities of building or strengthening an adult and older adult immunization
platforms. Key conclusions of the meeting were that there is a need for discussion of new opportunities
for vaccination of all adults as well as for vaccination of older adults, as reflected in the recent shift by
WHO to a life-course approach to immunization; that immunization in adults should be viewed in the
context of a much broader model based on an individual’s abilities rather than chronological age; and
that immunization beyond infancy is a global priority that can be successfully integrated with other
interventions to promote healthy ageing. As WHO is looking ahead to a global Decade of Healthy
Ageing starting in 2020, it will seek to define a roadmap for interdisciplinary collaborations to integrate
immunization with improving access to preventive and other healthcare interventions for adults
worldwide.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vaccination of older adults has been shown to reduce transmis-
sion and serious disease caused by vaccine-preventable diseasesmainly in high income countries (HIC), but the policy of vaccinat-
ing this age group has not been widely implemented in LMICs.
The World Health Organization (WHO) convened a meeting in
March 2017 to review policies on immunization of adults (with a
focus on older adults), to discuss vaccine performance in this group
and to review the pipeline of vaccines under development that
might be of benefit to adults and older adults in the future. While
the meeting was relevant to HICs as well as LMICs, the focus was
intentionally on the latter. The only vaccines with WHO recom-
mendations for specific use in elderly adults are influenza vaccines
[1], therefore influenza and influenza prevention represented anMarch
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cine policy and implementation needs globally. Finally, the meet-
ing aimed to discuss the challenges and opportunities for
strengthening adult immunization in LMICs and to identify activi-
ties and policies that can be pursued to this end.
This was the first WHO meeting on older adult immunization
since 2011 [2]. The objectives of the meeting were the following:
(1) to review policies on immunization of adults, with a focus on
older adults; (2) to discuss the incidence and determinants of vac-
cine preventable diseases in adults; (3) to discuss vaccine perfor-
mance in older adults and the pipeline of vaccines under
development that may be of benefit to adults and older adults;
(4) to discuss challenges and opportunities for strengthening an
adult immunization platform in low- and middle-income coun-
tries; and (5) to identify policies that could be developed and activ-
ities that can be pursued to promote access to vaccination for older
adults in LMICs. Participants included academic and industry
researchers, funders, civil society organizations, implementers of
global health interventions, and stakeholders from developing
countries with adult immunization needs. The agenda and list of
participants are in the Online Supplement. The two-day meeting
was organized around a series of background topic areas, followed
by case studies in LMICs, and then discussion on data needs for
policies and investments of vaccine programs targeting older
adults. This report is based on presentations and discussion from
the meeting.
2. Ageing and vaccination
2.1. Changing demographics and markets for vaccines
The world population is ageing. The number of individuals aged
60 and older is predicted to increase from 600 million to 2 billion
from 2000 to 2050, with 80% of older adults living in developing
regions [3], with a preponderance of women [4]. As people age,
they develop increased susceptibility to many infectious diseases.
As part of a broad public heath strategy the number of vaccine
doses needed to target older adults is anticipated to outpace those
needed by routine pediatric immunization programs.
Some countries are developing plans for this demographic
change, but many countries do not have vaccination policies
specifically targeting adult populations. Even in HICs, vaccination
use in adults can be low [5]; for example, despite a WHO recom-
mendation, only 45% of 115 member states with an influenza pol-
icy include programs targeting the ‘‘elderly” risk group, and most
of these are HICs [6].
For the purposes of this report, older adults are defined as peo-
ple in the second half of their life, i.e. over half of the life expec-
tancy for a particular country. While examples and discussionPlease cite this article in press as: Teresa Aguado M et al. Report on WHO mee
2017. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2017.12.029specific to older adults are provided in this report, sometimes
when the data specific to older adults are sparse or when discus-
sion of a broader age group is warranted, the report refers to all
adults.
2.2. WHO vaccine recommendations and age
Current WHO guidance on routine vaccines, summarized in
WHO vaccine position papers [7], focuses heavily on pediatric
immunization. There is some consideration of immunization in
pregnancy, immunization in health-care workers, high-risk occu-
pations, notes on travel vaccines or regional use, but few recom-
mendations for vaccination to protect adults in general against
infectious diseases, with the exception of a permissive recommen-
dation for influenza vaccine use in elderly persons and persons
with chronic disease. The older target group is not defined by
WHO, and countries have implemented ‘‘elderly” influenza vaccine
programs beginning at a variety of ages (including 50, 60, and 65
years).
WHO has a mandate within the Global Vaccine Action Plan
2011–2020 to ‘‘improve health by extending by 2020 and beyond
the full benefits of immunization to all people, regardless of where
they are born, who they are, or where they live” [8]. Furthermore,
the WHO Initiative for Vaccine Research (IVR) has long been inter-
ested in immunization of older adults, and has held and con-
tributed to relevant meetings on the topic over the past decade
[2], which have influenced the research agenda worldwide. Of
the major data gaps previously identified, most still remain [2].
These include disease burden data for many vaccine preventable
diseases in older adults, duration of protection of routine childhood
vaccines among older adults, performance of new vaccines target-
ing older adults within LMIC contexts, and how to identify the opti-
mal time for immunization of older adults to ensure sufficient
immunologic response and memory.
One goal in the WHO’s Global Strategy and Action Plan on Age-
ing and Health [9] is to design interventions to prevent disease and
to influence trajectories of individuals’ intrinsic capacity (defined
as a combination of one’s physical and mental capacities). One of
the important activities to promote healthy ageing is to ‘‘ensure
access and affordability of medical products, vaccines, and technolo-
gies” as part of integrated care for people in the second half of life
[10].
2.3. Definitions: at what age are people considered old?
Healthy ageing is defined by theWHO as ‘‘the process of develop-
ing and maintaining the functional ability that enables wellbeing in
older age” [11]. This ability depends on both an individual’s physi-
cal and mental capacities and on the environments one inhabitsting on immunization in older adults: Geneva, Switzerland, 22–23 March
M. Teresa Aguado et al. / Vaccine xxx (2018) xxx–xxx 3(for example access to transport and assistive devices) [10]. As
described in the WHO’s World Report on Ageing and Health [11],
while intrinsic capacity tends to decline with increasing age, a pri-
mary characteristic of older ages is great diversity. Even in the
poorest settings, an eighty year old may be healthy, independent,
and vibrant, while a sixty year old may need significant care and
support. Chronological age is thus a poor marker of health state,
and there is no fixed age when someone becomes ‘‘old”. Further-
more, this diversity is often a consequence of the cumulative
impacts of advantage or disadvantage across a person’s life. This
means that those with the greatest health needs in older age
may have the least access to the specific required resources.
In any population in the second half of life, three groups can be
proposed: those with high and stable capacity; those with decreas-
ing capacity; and those with substantial loss of capacity [10],
although individuals can transition between these states. Rather
than defining target groups for vaccination solely by their chrono-
logical age, assessing an individual’s level of capacity may add
important information on their need for vaccination, response to
vaccination, or the functional benefits likely to arise. For example,
where a vaccine is currently recommended for those above 65
years [12], some individuals may benefit from vaccination at an
earlier age because of declining capacity. While implementing this
approach would require development and adoption of simple and
robust measures of capacity in a clinical setting, discussions of this
topic may be beneficial in order to better understand optimal tar-
get groups for vaccination.3. Reasons for vaccination of adults and older adults
Discussion in the meeting highlighted many reasons and bene-
fits for vaccinating older adults and, indeed, any age group after
infancy (see Table 1).3.1. Examples of benefits of vaccinating older adults
Respiratory pathogens, such as Haemophilus influenzae type b
(Hib), influenza virus, respiratory syncytial virus (RSV) [13] and
Streptococcus pneumoniae [14–16] are key targets for vaccine
development and implementation in older adults in HICs, and vac-
cination of adults or older adults should have an impact on the bur-
den of these diseases in LMICs.
When studied from 2005 to 2008, influenza activity in Thailand
correlated with hospital admissions and deaths in older adults.
This finding led to a policy of administering domestically-
manufactured influenza vaccines to high-risk older adults
[17,18]. Similar studies have been conducted in Central America
[19], Ghana [20], and India [21], demonstrating the burden of dis-
ease in older adults and the unrealized potential impact of vaccine
programs targeting them. There are more limited data on other
respiratory infections in older adults; for example, two Thai studies
[16,22] found many hospitalized Streptococcus pneumoniae cases
were in older adults and authors called for cost effectiveness data
to inform future vaccine use.
In some cases, childhood vaccination can affect disease in older
adults due to population (herd) immunity, providing sufficient vac-
cine effectiveness (VE) and coverage can be achieved. This has been
observed with influenza vaccination in Japan [23] and the United
States [24]. In some settings, it has been suggested that a highly
effective infant influenza vaccination program might make vacci-
nating older adults unnecessary [25], but further data are neces-
sary. Another vaccine example is the a substantial positive
impact of pneumococcal vaccination of infants and children on
mortality and morbidity of seniors which was observed in the Uni-
ted States [26].Please cite this article in press as: Teresa Aguado M et al. Report on WHO mee
2017. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2017.12.029Another benefit of vaccinating people of all ages is an indirect
effect on the ability of microbes to resist the effects of drugs, or
anti-microbial resistance (AMR). The Global Action Plan on AMR
[27] states that immunization could reduce AMR in three ways:
first, by using existing vaccines to prevent infectious diseases
whose treatment would require antimicrobials; second, by using
existing vaccines to reduce the prevalence of primary viral infec-
tions which are often inappropriately treated with antibiotics or
that can lead to secondary infections that require antibiotic treat-
ment [28]; and, third, by the development and use of new vaccines
targeting pathogens difficult to treat (or untreatable) due to AMR.
In addition, vaccination might selectively target resistant strains of
an organism, reduce the opportunity for pathogens to exchange
resistance genes, or reduce bystander selection of resistance in
normal flora species [29].
Several studies illustrate how existing vaccines can reduce
infections in vaccinees of all ages [30] and through population
(herd) immunity [31], but very few studies have been conducted
to measure vaccine effectiveness at preventing anti-microbial use
or AMR. As secondary outcomes of pneumococcal conjugate vac-
cine (PCV) use, some studies in infants in HICs have shown a reduc-
tion in antibiotic prescription [32], a reduction in antimicrobial
purchases [33], or reduced duration of antibiotic use [34]. Model-
ing studies have concluded that high coverage with PCV in 75
countries not currently achieving 80% coverage could avert many
millions of days of antibiotic use in young children [35].
Low-income countries (LICs) are at highest risk of AMR [36], so
vaccine use in those countries could potentially yield the greatest
benefits. There is, however, a significant lack of data on the impact
of vaccines on AMR in LICs, especially in older adults.
3.2. Health economics of vaccination of adults and older adults
Health economic evaluations such as cost-effectiveness analysis
are important tools for investigating whether the social and eco-
nomic benefits of an intervention such as vaccination outweigh
the opportunity costs of the intervention. However, evaluations
of vaccination of adults and older adults in LMICs are severely lack-
ing compared to similar evaluations of pediatric vaccination. For
example, two reviews of cost-effectiveness studies of seasonal
influenza vaccination found only five studies for older adults in
LMICs [37,38].
Many economic evaluations do not capture some of the broader
economic benefits of vaccination at the individual, household and
society level that are particularly relevant to adult vaccination.
For example, evaluations of the indirect benefits of vaccination
should consider the roles older adults play in the volunteer sector
and as caregivers in families and communities, looking after
infants and children as part of the ‘‘informal economy” [39]. These
aspects may be particularly valuable in LMICs [40]. In addition, tra-
ditional measures of health utility such as quality- or disability-
adjusted life years may not capture what older adults value most
about good health and maintenance of functional ability. Alterna-
tive measures of health utility for older adults have been proposed,
including independence, and ability to do the things that they
value [41].
The impact of population (herd) immunity adds a further level
of complexity to economic evaluations. In some settings, it might
be more cost-effective to protect older adults from an infection
by vaccinating infants to eliminate the infant reservoir of the
pathogen. Consensus guidelines for methodological approaches
to estimating direct and indirect costs of vaccine-preventable dis-
eases in LMICs are required, and are being developed by WHO
for influenza [42]. Similar guidance would be of value for other
vaccine preventable diseases that disproportionately affect older
adults.ting on immunization in older adults: Geneva, Switzerland, 22–23 March
Table 1
Reasons for vaccinating after infancy.
Reason Notes and examples
Improving population (herd) immunity and disease control
Catch-up - coverage with the complete schedule of infant vaccines is not
100%, leaving some of the population unprotected
Global burden of disease data for tetanus mortality, showing that most cases are in LMICs
and deaths are at all ages [88]
The vaccine(s) in question might not have been in use while the adult
population were infants
Applies to recent vaccine introductions, such as measles, mumps and rubella (MMR),
hepatitis B virus, varicella zoster virus, and pneumococcal conjugate vaccine
Protection against pathogens with changing strains or serotype prevalence
that might differ in different age groups
Examples include: influenza and Streptococcus pneumoniae (pneumococcus)
Protecting at-risk populations after childhood
Protection against occupation-associated exposure to specific pathogens Especially healthcare workers, food handlers, laboratory workers, but also those with
close contact with animals
Prevention of infections in hospitalized patients Examples include: Methicillin-resistant Staphylococcus aureus; C. difficile; norovirus
Respiratory diseases can have serious impacts in adults/older adults.
Higher rates of morbidity or mortality with older onset of other
infections
There is a link between seasonal influenza and functional decline in activities of daily
living in people living in nursing homes in the USA, [89]. Varicella case fatality rate in
older adults is 25–174-fold higher, compared with children [55]
Risk of infection increases, or has higher morbidity, with chronic conditions An example includes, Hepatitis B and diabetes due to cross-infection in healthcare
settings [90]
Protection through the life-course
Vaccination of women before or during pregnancy to protect themselves
and their infants
Examples include: diphtheria, influenza, pertussis, polio, MMR, varicella, tetanus [91]
Vaccination to prevent unnecessary antibiotic use given the growing
concerns about antimicrobial resistance
The following pathogens have developed significant drug-resistance: Acinetobacter
baumannii, candida sp., C. difficile, diphtheria, Enterobacter sp., Enterococcus faecium,
Escherichia coli, gonococcus, Haemophilus influenzae type B, HIV, Klebsiella pneumoniae,
malaria, meningococcus, Mycobacterium tuberculosis, Pseudomonas aeruginosa, typhoidal
and non-typhoidal Salmonella, Shigella sp., Staphylococcus aureus, tetanus
Vaccination of travelers Examples include: hepatitis A virus, polio, typhoid, yellow fever, and others
Prevention of chronic and latent infections Examples include: Mycobacterium tuberculosis, herpes simplex virus, varicella zoster
virus, hepatitis B virus [92]
Secondary prevention of non-communicable diseases (NCDs) Some infections are being linked to causality of NCDs. Influenza vaccination could reduce
cardiovascular events in at-risk people, including the middle aged [93,94]. Influenza
vaccine reduced major cause-specific mortality (stroke, renal disease, diabetes, pneu-
monia, chronic-obstructive pulmonary disease, malignancy and heart disease) in
Taiwanese older adults [95]
Deterioration of the immune system with age could compromise the
homeostatic equilibrium between microbiota and host
Reduced bacterial diversity in the gastrointestinal tract is correlated with C. difficile-
associated diarrhea [55]
Vaccines needed for protection against emerging diseases, outbreaks and
pandemics
Examples include chikungunya, cholera, Ebola, Middle East respiratory syndrome, severe
acute respiratory syndrome, pandemic influenza, tick-borne encephalitis and Zika
Note: Gathered from presentations and discussion at the WHO meeting.
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4.1. Vaccine performance in older adults
Vaccine performance can be measured by vaccine immuno-
genicity, efficacy, or effectiveness. Vaccines can be less immuno-
genic in older adults due to immunosenescence (see Section 4.2).
Concomitant anti-inflammatory and immunomodulatory therapies
are more likely to have significant negative interactions with vac-
cines in older adults [43]. Immune responses (and adverse reac-
tions) to vaccines tend to be higher in females than males, and
loss of function with age might be more frequent or of greater
magnitude in males [4]. At all ages, vaccine effectiveness tends to
be higher in women than in men [4].
Often vaccines have a lower vaccine effectiveness in older
adults compared to younger adults, and several approaches have
been used to overcome this: (a) increasing the number of doses
administered, (b) increasing the dose of antigen in the formulation,
and (c) incorporating adjuvants, such as MF59 in the Fluad sea-
sonal influenza vaccine [44]. It has been proposed that early-
season use of influenza vaccines might result in antibodies that
wane by the start of a late-season virus circulation [45] so the tim-
ing of vaccination could also be important.Please cite this article in press as: Teresa Aguado M et al. Report on WHO mee
2017. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2017.12.029The performance of seasonal influenza vaccines in older adults
has been reviewed in several meta-analyses [46,47], and vaccine
effectiveness has been observed to be suboptimal compared to
other age groups. However, recent systematic reviews of the use
of adjuvanted influenza vaccine formulations [44] and intradermal
administration [47] have shown improved immunogenicity of sea-
sonal influenza vaccines in the elderly. These studies have been
conducted in HICs and less data are available on influenza vaccine
use in adults in LMICs [48]. PCV and pneumococcal polysaccharide
vaccine (PPV) effectiveness have also been reviewed; PPV effective-
ness was found to be 50% [30] and PCV effectiveness was 48.5% in
preventing invasive pneumococcal disease in healthy adults aged
65 years and over [49].
Analyses have shown that the high-dose influenza vaccine in
older adults (Fluzone, Sanofi Pasteur) performs better in older
adults than the standard influenza vaccines [50]. It has a higher
VE, and induces higher antibody responses in adults aged more
than 65 years compared with the standard formulation (60 mg HA
vs 15 mg HA per dose). A supplementary analysis showed the
high-dose vaccine was better at preventing serious cardio-
respiratory events and pneumonia than the standard vaccine
[51], and a retrospective cohort study in the United States found
the vaccine to be more effective than the standard dose vaccineting on immunization in older adults: Geneva, Switzerland, 22–23 March
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admissions, and death in adults 65 years of age and older [52–54].Table 2
Examples of licensed vaccines, or vaccines in development, for use in adults– by stage
of development, as of 2017.
Stage Vaccines
Preclinical Influenza, Respiratory syncytial virus
Phase I Clostridium difficile, HIV, Respiratory syncytial virus
Phase II Ebola, Enterotoxigenic Escherichia coli, Extra-intestinal
pathogenic Escherichia coli, HIV, Norovirus, Respiratory
syncytial virus, Staphylococcus aureus, Streptococcus
pneumoniae (pneumococcus),
Phase III Clostridium difficile, Varicella zoster virus
Licensed Diphtheria tetanus pertussis, Hepatitis A virus, Hepatitis B
virus, influenza, meningococcal meningitis, pneumococcus,
Varicella zoster virus, Haemophilus influenzae type b
Not publicly
known
Group B streptococcus, Zika virus
Notes: Vaccines exclusively for maternal immunization to protect newborns and
cancer immunotherapies have not been included. Vaccines for pathogens in bold
were discussed at the WHO Product Development for Vaccines Advisory Committee
2016 meeting; references are on the meeting website [96] See also the WHO
Vaccine Pipeline Tracker [97] for references for dengue, Ebola, enteric diseases, HIV,
malaria, Mycobacterium tuberculosis, Respiratory syncytial virus, Zika virus and
other priority emerging pathogen and WHO information on vaccines and diseases
for landscape analyses [98].4.2. Immunosenescence and biomarkers
Studies of immunosenescence in preclinical models and
humans have identified many aspects of adaptive and innate
immune responses that decline or change with age [55]. Biomark-
ers for these changes have the potential to inform more rapid vac-
cine development for older adults. The number of naïve T
lymphocytes declines with age, following involution of the thymus
after puberty, compromising the ability to respond to new vaccina-
tions (or infections). It has also been suggested that the expanded T
cell responses required to keep persistent infections controlled,
such as Epstein Barr virus and human cytomegalovirus (HCMV),
reduces ‘‘space” for new T cells, particularly CD8+ T cells [55];
however, the effect of HCMV infection on immune function, includ-
ing the response to influenza vaccine, appears to be heterogeneous,
and is seen only in older individuals who might have had persis-
tent HCMV infection for decades [56]. Recently, older adults were
shown to have increased senescent and exhausted varicella zoster
virus (VZV)-specific T cells which may contribute to their inability
to prevent VZV reactivation and the subsequent development of
herpes zoster [57].
The number and function of B lymphocytes also decreases with
age, with an increase in the number of late/exhausted B cells that
are terminally differentiated, non-proliferating and with poor
effector function [58,59]. Many immune cell types express a
senescence-associated secretory phenotype, defined as the secre-
tion of several pro-inflammatory cytokines including tumor necro-
sis factor alpha, interleukin 6 and interleukin 8 [55,58], which
promotes chronic low-grade inflammation. Numbers of dendritic
cells (DCs) and Langerhans cells decline [60], and DCs exhibit
reduced phagocytosis and class 1 human leucocyte antigen expres-
sion [55].
These changes in immune function have been shown to impair
primary responses to yellow fever (YF) vaccine in travelers, even
though protective levels were still achieved [60]. Memory immune
responses, such as to seasonal influenza vaccine, have also been
shown to be affected [58].
Despite immunosenescence, it is still possible to induce
immune responses in older adults that are protective or equivalent
to those seen in younger age groups; examples include: (a) phase
III trials of the two-dose HZ/Su subunit vaccine branded as ‘‘Shin-
grix” against herpes zoster that showed similar vaccine efficacy
in ages 50 years and older [61] and 70 years and older (90%)
[62]; (b) phase I/II trial of a candidate Staphylococcus aureus single
dose, non-adjuvanted, inactivated vaccine in healthy adults aged
65 –85 years showed that functional antibody responses which
met pre-defined thresholds in the older adults [63]; and (c) two tri-
als with different Clostridium difficile vaccines that showed similar
responses across different age groups [64,65].
Identification of biomarkers of immunosenescence might
inform rational design of vaccines, for example those that include
novel adjuvants, to enhance immune responses in older adults,
or could be used to identify individuals who are unlikely to
respond to a given vaccine. Systems approaches in biology research
are being used to identify such markers [66]. Data obtained to date
suggest that the changes observed in immunosenescence are also
found in many fundamental biological pathways such as cell prolif-
eration and hormone regulation as well as lymphocyte activation
and differentiation [66].
Although most of the data on ageing and immunosenescence
have been collected in HICs, a pilot study conducted in Pakistan
found similar changes in immune cell phenotypes in young (agedPlease cite this article in press as: Teresa Aguado M et al. Report on WHO mee
2017. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2017.12.02918–28 years) and older (aged 50–85 years) men, to those seen in
HICs [67].5. Vaccines that are or could be of benefit to older adults
Multiple licensed vaccines are currently used in adults,
although they remain underused in the general adult population
and in some target groups. In addition, there are new vaccines
for adults in the development pipelines of many vaccine manufac-
turers (Table 2).
Some of the vaccines in Table 2 are of interest for people of any
age with low intrinsic capacity, such as Staphylococcus aureus [68];
extraintestinal pathogenic Escherichia coli, because of its role in uri-
nary tract infections [69]; and C. difficile, because of its high mor-
bidity and mortality, especially in older adults. These three
pathogens are also important targets from the perspective of
reducing AMR.6. Considerations for vaccination of adults and older adults in
LMICs
As stated above, much of the data on the need for, and use of,
vaccines for adults comes from studies in HICs. There are, however,
important differences between HIC and LMICs that need to be
taken into consideration, including specifics related to adult immu-
nization in terms of disease epidemiology, health infrastructure,
opportunities for life-course immunization, and policymaking in
this age group.
6.1. Disease epidemiology and comorbidities
The epidemiology and timing of infectious diseases can be very
different in LMICs, based on factors such as differential exposure
due to climate, geography and hygiene and an earlier risk of expo-
sure to a diverse and larger number of pathogens. In addition, co-
infections such as tuberculosis or human immunodeficiency virus
(HIV) can affect the risk of severe outcomes from vaccine pre-
ventable diseases as well as the immune response to vaccines
[70]. Immune responsiveness can also be affected by differences
in nutrition, such as vitamin A deficiency [71], and obesity [72].
There is also evidence, albeit in infants, that diet, exposure to
microorganisms and parasites, and anti-microbial (and anti-ting on immunization in older adults: Geneva, Switzerland, 22–23 March
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there may be a myriad of environmental conditions that result in
a different picture of co-morbidities of infectious diseases and
other non-communicable diseases (NCDs) and conditions in LMICs
compared with HICs. Reduced access to healthcare and social ser-
vices in LMICs can also affect an individual’s functional capacity at
any age, and can limit access to vaccination.
6.2. Health infrastructure for adult vaccination
The implementation in 1974 of the Expanded Programme on
Immunization (EPI) has meant that routine immunization infras-
tructure has focused on neonates, infants (e.g. immunization visits
at ages 6, 10 and 14 weeks, and 9 months) and pregnant women.
Achieving high vaccination coverage in target groups outside the
traditional program can be difficult. Countries considering
strengthening immunization platforms for older adults would ben-
efit from strategies and lessons learned from similar efforts in
other age groups [74]. Currently, more than 80 countries have
introduced human papillomavirus (HPV) vaccine into their
national immunization programs, usually with school-based vacci-
nation; 33 of these are LMICs, and an additional 25 LMICs are
undertaking pilot programs prior to full scale introduction [75].
Lessons learned from HPV programs [76], including the usefulness
of pilots or demonstration projects [77], could be valuable for
establishing new platforms for adult vaccines, especially ones
where multi-dose regimens are required [78]. For example, adults
taking infants to a pediatric vaccination clinic could also be offered
immunizations or other services.
6.3. Opportunities within life-course immunization in LMICs
A major barrier in many LMICs is that there is often not a com-
prehensive health system to reach all adults, including older
adults, for preventive healthcare. If one could be established, it
could have many benefits for all kinds of health interventions,
including screening, diagnostics and treatments.
There is interest within the vaccine community, and those
whose primary focus is the health of older adults in general, on
new opportunities to build preventive and other healthcare ser-
vices around or including immunization. Life-course immunization
may include the following healthcare points and systems: well-
baby, school-entry, school-leaving, general practice, community
pharmacies [79], community nurses, adolescent health, universi-
ties and colleges, ante-natal care, outpatient clinics for the chron-
ically sick, nursing homes, military services, services for new
migrants, and travel vaccination clinics.
Many healthcare systems may benefit from increasing attention
on disease prevention, particularly in LMICs. Increasingly, there is
anticipated to be a shift to self-management of and prevention of
medical conditions, with individuals taking more responsibility
for their health, which could include demanding vaccines for
themselves or their parents or other family members.
6.4. Mandates and policymaking
Although adults and older adults are not often explicitly identi-
fied as target groups for vaccination, they are included in global
strategies and policies. The stated vision of the Decade of Vaccines
(2011–2020) is for ‘‘a world in which all individuals and communities
enjoy lives free from vaccine-preventable disease” [8]. In addition,
Goal 3 of the United Nations Sustainable Development Goals [80]
is to ‘‘ensure healthy lives and promote well-being for all at all ages”,
and includes a target of ‘‘access to safe, effective, quality and afford-
able essential medicines and vaccines for all”.Please cite this article in press as: Teresa Aguado M et al. Report on WHO mee
2017. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2017.12.029Despite broad, bold policy statements, however, there is often
delayed uptake of new vaccines for some target groups and ages
for a variety of reasons [81], some of which are especially applica-
ble to adult vaccination. For example, successful introduction of
any new vaccine requires engagement and alignment of multiple
stakeholders. Governments must see the value in a new vaccine
before they are willing to introduce it and this requires recognition
of the burden of disease and the fact that an affordable, deliverable
vaccine is available. Purchasers (donors, governments or private
health providers) are unlikely to pay for the vaccine unless they
think it will be seen as a priority by end users, and vaccine devel-
opers and manufacturers will not produce the vaccine unless they
believe it will be purchased. Other reasons relate to the general
lack of awareness by adults that vaccine-preventable diseases such
as pneumococcal pneumonia, influenza and shingles can have dev-
astating effects on the health, function and socioeconomic contri-
butions of a normal healthy older person, let alone those who
may have a chronic condition such as diabetes.
To promote influenza vaccination of older adults, for example, it
might be important to recognize that seasonal influenza infections
do not just result in a short-term increase in accelerated mortality,
but also result in low-quality of life and morbidity that can extend
for several months after the influenza season [82]. The costs of the
social and economic burden need to be quantified for the stake-
holders in question. In some situations, to stimulate uptake of vac-
cines for an ageing population, it might be preferable to re-frame
the narrative to one that reflects the contributions that older adults
across society make with advancing age in good health or simply
their higher quality of life.7. Barriers to adult vaccination
Adult vaccine coverage is low, even in HICs, for a variety of rea-
sons [83]. Perceived and actual barriers can be categorized at the
level of the individual and community demand for vaccines, or
with the vaccination process and system (Table 3). This list of bar-
riers has been modified from a prior publication [79], with addi-
tional information based on presentations and discussion at the
meeting. Some of the barriers apply to vaccination of all age
groups; others are specific or more relevant to vaccination of
adults.
Despite the barriers to vaccination after infancy, some which
are listed in Table 3, many countries are gaining experiences that
should be useful in the future and to other countries [84]. The
International Federation on Ageing’s World Coalition on Adult Vac-
cination [85] is one of several global and regional projects aiming
to help improve uptake rates of adult vaccination through building
an understanding of the community and systemic barriers and
then working across sectors and disciplines to create solutions.8. Gaps in knowledge
One of the objectives of the meeting was to identify challenges
and opportunities for strengthening adult immunization in LMICs.
Significant gaps in knowledge regarding vaccination of adults and
older adults, particularly in LMICs, were identified (Table 4). Most
of the existing data that are available come from HICs, or a limited
number of MICs (Brazil, China, India, Mexico, Thailand). Some MICs
have parts of their population with some characteristics of HIC and
other parts that are under-developed. They could represent good
settings to compare interventions in different subpopulations of
the same country exposed to different conditions.ting on immunization in older adults: Geneva, Switzerland, 22–23 March
Table 3
Barriers to vaccination – including barriers specific to adult vaccination, WHO meeting on immunization in older adults, March 2017.
Category Barrier Response
Evidence for
action
Lack of burden of disease and economic data and/or policy
recommendations; weak value proposition
Generate burden of disease data, evidence of VE; strong statement(s) from
trusted source (e.g. WHO); promote evidence to national immunization
technical advisory groups (NITAGs) and medical associations
Individual
factors and
information
Vaccine hesitancy or lack of awareness and action due to insufficient
information, knowledge, skill, or time; or too-complex information
Improve communication methods, inform and motivate communities.
Increase access to vaccine information, preferably with tailored information
Vaccination
process
Adult vaccine schedules (or information) can be highly complex.
Pathways to access vaccination can be complex, vaccinees might
need to make several visits to get prescription, supplies and then
vaccination itself.
Infant programs are often prioritized by communities and
governments
Simplify schedules or explain better. Integrate vaccination history with
electronic medical records. Simplify and bring services closer to where adults
live, work, study or currently seek medical care (e.g. ante-natal clinics).
Self-administration of vaccines could overcome some immunization logistics
obstacles
Vaccination
system
Limitations in vaccination infrastructure are widespread and
include:
 Lack of advice for National Immunization Technical Advisory
Groups from experts in adult vaccination
 Lack of public sector support for adult vaccines and limited pro-
motion of adult vaccination
 Limited resources to purchase and deliver adult vaccines. In
many countries adults ‘‘self-pay” for vaccines.
 Few providers stocking adult vaccines, e.g. for fear of wastage
[99].
 Low healthcare practitioner awareness and leadership, in part
due to lack of training.
 Territorial limitations. In some settings, only some healthcare
professions can vaccinate.
 Financial constraints and/or inconsistent reimbursement
schemes
Improve vaccination infrastructure, as was done in Nigeria [100].
Obtain political commitment for vaccination. Implement fair reimbursement
systems.
Establish vaccination advocates and champions.
Change in the focus of healthcare, in general, to reflect ageing populations.
Promote benefits to funders so no economic barriers to end-user. Programs
must be fully funded, to cover all doses in schedule.
Change workflows to incorporate adult vaccination; establish new infras-
tructure for accessing vaccines, including out-of-school.
Education and training of healthcare workers and encouragement to be fully
vaccinated themselves; promote adult vaccination as a professional norm
Community
perception
In some settings, society places a lower value on the health of older
people than that of children [101,102]
Promote change in societal values to recognize intergenerational connections
Notes. The list is modified from [79]. The focus on barriers and responses for adult vaccination was gathered from presentations and discussion at the meeting.
Table 4
Gaps in knowledge supporting decision-making for adult and older adult immunization in developing countries.
Gap in Knowledge Comments
Burden of disease
What is the true burden of disease for infections that might be preventable in
adults and older adults, especially in low- and middle-income countries
(LMICs)?
Encourage gathering and sharing of data on broad measures of health (not just
deaths due to disease); consider exacerbation of co-morbidities such as
cardiovascular disease and chronic obstructive pulmonary disease
What are the broader impacts of vaccine-preventable diseases in older adults? Large, long-term cohort studies are required to evaluate the impact of vaccine
preventable diseases (and of vaccination) on frailty and relevant measures of
quality of life, health care expenditure and wider social costs
Benefits of immunization for adults and older adults
Are there associations or causal links between infectious disease and non-
communicable diseases (NCDs), and what is the impact of vaccination
including in older adults?
NCD endpoints (including frailty) could be incorporated in vaccine trials, using
measures appropriate for LMICs. Observational studies could also be informative
What are the broader economic benefits of vaccination in older adults? As well as standard measures, there is a need to determine how to measure the
economic value of adults at different ages, including in informal economy (e.g. as
caregivers).
It is important to assess indirect economic value by preventing disease and
disability, as well as by preventing exacerbation of existing co-morbidities. Patient
and household surveys can help to identity the socioeconomic contribution of
older adults
What data are available the impact of adult vaccines on anti-microbial use in
LMICs?
With sufficient baseline data, reduction in antibiotic use could be used as an
endpoint in clinical studies of vaccines
Immune responses in adults and older adults
How does immune function change with ageing? Is the process of immunological
ageing the same in HICs and LMICs?
Systems approaches could be applied to studying the biology of
immunosenescence [103]
What are the impacts of obesity and other age-related or life-style conditions
(nutrition, social isolation, emotional distress, physical activity) on immune
function?
Different populations in high-income countries (HICs) and LMICs and with
different co-morbidities should be compared
To what extent do commonly used (adult) medications have an impact on immune
responses to infection and vaccination?
As an example, the response to influenza vaccines in people taking statins is
altered and may be lower [104,105]
(continued on next page)
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Table 4 (continued)
Gap in Knowledge Comments
Can we measure frailty, intrinsic capacity and environmental factors? Do we have
the necessary tools and are they validated?
Observational and interventional studies with vaccines could examine the
potential links between these factors and prevention of disease or decline?
Interrelationships between pediatric and adult vaccination programs
Should the need for and frequency of booster doses for infant vaccines during
adulthood be revisited?
Examples include long-term immunogenicity and efficacy data for acellular
pertussis [106] and tetanus vaccines
What is the potential impact of population (herd) immunity from vaccination of
children on the need to vaccinate older adults?
In HICs, the value of infant/childhood conjugate vaccination (Pneumococcal
conjugate vaccines, Haemophilus influenzae type b vaccines) has resulted in
decreased disease burden in adults. More studies on population effects of seasonal
influenza and pneumococcal vaccination of infants and young children are needed,
especially in LMICs
What is the potential impact of pediatric varicella vaccination on herpes zoster in
adults?
There have been suggestions that exposure to varicella may boost immunity to
herpes zoster but the strength of this effect and its implications for vaccination are
still being debated [107]
Program implementation
What are the major hurdles in communication to create awareness of the benefits
of adult immunization?
Training of health care personnel and appropriate communication at all levels
(policy makers, health care personnel, and patients/society will be required
What vaccine delivery platforms are best for achieving high coverage? Reaching target vaccination groups outside the traditional infant vaccination
requires new strategies, delivery locations, and effective communication to
promote community demand
8 M. Teresa Aguado et al. / Vaccine xxx (2018) xxx–xxx9. Conclusions
There are global mandates to expand and strengthen immu-
nization in older adults, however critical data to inform policy
making and public health practice in LMICs remain limited. More
data are needed on vaccine-preventable disease burden in older
adults in LMICs and the estimated impact vaccines would have
on this burden. Further, new ways to look at impact of vaccine pro-
grams, that take into account the contributions of healthy older
adults and the consequences of their declining intrinsic capacities
to society, are needed. Two clear conclusions from the meeting
were that immunization of adults should be viewed as a key com-
ponent of a comprehensive approach to health, and that protecting
older adults from vaccine-preventable diseases might mean
achieving high vaccine coverage in all age groups (including
infants), and not simply older adults. Additionally, the need for
vaccine research and development related to immunosenescence
was identified, given the remarkable increase in the population
of older adults.
To achieve significant increases in adult vaccination coverage,
the knowledge gaps listed in Table 4 should be addressed. Equally
important will be the need for a shift in overall thinking about pro-
viding protection against vaccine-preventable diseases, which has
to date focused nearly exclusively on vaccination of infants [86].
Activities to improve coverage with infant vaccines should not
diminish, but an increasing emphasis needs to be placed on life-
course approach to immunization schedules to protect adults and
older adults, especially given the significant and changing demo-
graphics of the global population. There is already some evidence
from HICs of the benefits of using existing vaccines in older adults
[49,82]. Although the efficacy of some vaccines might be lower in
older adults than is usually seen with infant vaccines, these data
need to be viewed in the context of the increased risks from dis-
ease and broader social and economic benefits of prevention in
older populations. Misconceptions about the benefits of vaccina-
tion of older adults should not prevent its use.
Decreasing adult preventable disease through improved uptake
of appropriate vaccines will require strong champions, both indi-
vidual and institutional [87], at a time when there are many com-
peting priorities for health spending. Obtaining data is critical to
gaining a deeper understanding of the impact of adult vaccinationPlease cite this article in press as: Teresa Aguado M et al. Report on WHO mee
2017. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2017.12.029on problems such as AMR, as well as the growing need to guard
against preventable illnesses in an ageing global population with
co-morbidities and concomitant conditions. The ‘‘business case,”
that is, the direct and indirect associated health-care and broader
societal costs and benefits, is critical to justify a life-course
approach to vaccination. Raising awareness of the importance of
vaccination of adults and older adults is just the beginning of truly
cementing the interventionwithin a broader public health strategy.
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